📰 3 sources covering this story

Lilly’s revenue soars 48%, driven by demand for its GLP-1s

First covered 14 hrs ago · latest take 1 hrs ago. Compare how each outlet is covering it — and rate the sources you trust.

MarketWatch1 hrs ago

Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.

Trust?Read on MarketWatch ↗

Wall Street Journal1 hrs ago

Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand - WSJ

Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand WSJ

Trust?Read on Wall Street Journal ↗

Channel NewsAsia🏁 first to report14 hrs ago

Arista forecasts upbeat quarterly revenue on AI-driven networking demand

Aug 4 : Arista Networks forecast third-quarter revenue above Wall Street estimates on Tuesday, betting on strong demand for its networking gear as companies expand their AI infrastructure.The company has been expanding beyond its core cloud customer base into enterprise campus and branch networking to diversify its rev

Trust?Read on Channel NewsAsia ↗